NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Yulinzhu for Women With Diminished Ovarian Reserve

RecruitingPhase 3

Sponsor: The University of Hong Kong

Conditions: Diminished Ovarian Reserve (DOR)

Interventions: Yulinzhu (a Chinese Medicinal Formulae)

Countries: Hong Kong

This is a randomized waiting-list controlled crossover trial carried out to investigate the efficacy of traditional Chinese medicine (TCM) for DOR and its potential beneficial effects on fertility. Subjects' (1) Ovarian function (AMH, FSH), (2) Bilateral AFC as shown in pelvic ultrasound, and (3) Traditional Chinese Medicine Symptom Score (TCMSS) will be recorded. It is hypothesized that a 12-week course (5 days medication per week) of TCM herbal therapy for DOR patients will improve one or more of the above aspects when compared to the waiting-list control group.

Eligibility overview

Sex: FEMALE

Age: 18 Years to 40 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Women aged 18-40, with regular menstruation (cycle from 21 to 35 days) and reduced fertility (infertility, early miscarriage, recurrent pregnancy loss, recurrent implantation failure, etc.) ;
2. Tests of ovarian reserve within 6 months:

   1. AMH \< 1.1 ng/ml or (any day in cycle, refer to laboratory standards);
   2. AFC \< 7 follicles or (any day in cycle);
   3. Received \<3 cycles of IVF in public sector;
3. Subject has no history of allergy to TCM;
4. Subjects agree to receive IVF treatment upon the completion of this research within 12 weeks if they are not pregnant spontaneously; and
5. As diagnosed by Chinese Medicine practitioner through four diagnostic methods, suitable to receive Yulinzhu.

Exclusion Criteria:

1. Previous history of a unilateral or bilateral oophorectomy;
2. Recent administration of TCM for DOR within 3 months;
3. Diagnosis of pregnancy, premature ovarian failure, residual follicles, cysts or space-occupying lesions in the ovary, pelvic inflammatory disease or polycystic ovary syndrome; and
4. Cancer, untreated thyroid dysfunction, severe cardiovascular/cerebrovascular diseases, severe liver/kidney diseases or hematopoietic system diseases.
5. Subjects are allowed to withdraw from the trial for one of the following reasons:

(1) The patient fails to complete treatment due to safety or medical reasons; (2) The patient fails to follow treatment guidelines; (3) The patient is unwilling to continue treatment for any reason.

Locations (2)

Hong Kong, Hong Kong
Hong Kong, Hong Kong